The OncLive COVID-19 condition center page is a comprehensive resource for clinical news and expert insights on how the COVID-19 pandemic has impacted multiple areas of oncology care and practice. This page features news articles, interviews in written and video format, and podcasts encompassing data of patients with COVID-19 and cancer, oncology drugs being tested against the virus, vaccine information for patients with cancer, and more.
NCCN and ACS Call for Resumption of Cancer Screening, Treatment Amidst COVID-19 Crisis
January 28, 2021 - The National Comprehensive Cancer Network and the American Cancer Society are collaborating with cancer organizations nationwide to promote the resumption of cancer screening and treatment during the coronavirus disease 2019 pandemic.
NCCN Releases COVID-19 Vaccination Guidance for Patients With Cancer
January 22nd 2021All patients with active cancer, or with active, recent, or planned cancer treatment, should be considered highest priority to receive one of the coronavirus disease 2019 vaccines that have been granted emergency use authorization from the FDA.
COVID-19 Pandemic Restructures Care in CLL
January 12th 2021As the coronavirus disease 2019 pandemic continues to pose challenges, health care providers struggle with decisions on how to balance the risk of severe acute respiratory syndrome coronavirus 2 transmission with the need to treat patients’ underlying conditions.
FDA Advisory Committee Votes in Favor of COVID-19 Vaccine mRNA-1273
December 17, 2020 - The FDA’s Vaccines and Related Biological Products Advisory Committee has voted 20-0 with 1 abstention to support the benefit-risk profile associated with the coronavirus disease 2019 vaccine mRNA-1273.
FDA Advisory Committee Votes in Favor of COVID-19 Vaccine BNT162b2
December 10, 2020 - The FDA's Vaccines and Related Biological Products Advisory Committee has voted 17-4 with 1 abstention to support the benefit-risk profile associated with the coronavirus disease 2019 vaccine BNT162b2.
Patients With Hematologic Cancers at Increased Risk for Adverse COVID-19 Outcomes
December 6, 2020 — Patients with hematologic malignancies are at increased risk for significant morbidity and mortality from coronavirus disease 2019, and the risk of death appeared to be greatest in those who were older, had more severe infection, a poorer prognosis, or who decided to forego intensive treatment
Off-the-Shelf, SARS-CoV-2-Specific T Cells Display Antiviral Activity
December 5th 2020The effector profile of the SARS-CoV-2 virus–specific T-cell therapy, ALVR109, was polyclonal, polyfunctional, and displayed cytolytic activity against viral targets without allogeneic or autologous reactivity, suggesting ALVR109 could be a safe and effective treatment for the coronavirus disease 2019.
COVID-19 Sharpens Focus on Drug Holidays
Having patients go on drug holidays or intermittent therapy is a common strategy during treatment of prostate cancer and several other malignancies, whether to provide temporary relief from adverse effects influencing quality of life, to prevent long-term health impacts, or to lessen drug resistance that would render the therapy ineffective.
Pandemic Heightens Stress of Cancer Diagnosis
December 1st 2020The repercussions of delays in diagnosing cancer, either through screening or the presence of early symptoms, and of required modifications in standard-of-care management paradigms in the COVID-19 era are only now beginning to be fully appreciated.
Infrastructure of Oncology Care Model Helps Practice Through COVID-19
November 27th 2020Nothing about taking care of patients with cancer during the coronavirus disease 2019 pandemic has been easy, but those practices that had already embraced transformation under the Oncology Care Model are finding that its monthly payments and other features offer stability during an unprecedented health emergency.
Acalabrutinib Misses the Mark in Patients Hospitalized With COVID-19–Related Respiratory Symptoms
November 18, 2020 - The addition of the oral BTK inhibitor acalabrutinib to best supportive care in patients with respiratory symptoms from coronavirus disease 2019 infection failed to increase the proportion of patients who remained alive and free of respiratory failure, missing the primary efficacy end points of the 2 phase 2 CALAVI trials.
Cancer Experts Spotlight the Significance of the Institutional Perspectives in Cancer Webinars
November 17th 2020The Institutional Perspectives in Cancer webinars assemble academic and community-based physicians and healthcare professionals across key disciplines, ranging from medical to surgical oncology.
Raez Raises Concerns Over Delayed Cancer Care in the COVID-19 Era
November 16th 2020In our exclusive interview, Dr. Raez discusses the reasons for the declines in routine screening and referrals due to the coronavirus disease 2019, anticipated consequences, and some of the ways in which the health care community can combat these newfound challenges.
French Study Sheds Light on COVID-19 Stress Among Patients With Cancer
November 13th 2020Patients on active therapy during the coronavirus disease 2019 pandemic, as well as oncology care providers, have increased levels of perceived and posttraumatic stress, according to preliminary data from the COVIPACT study.
Halmos Highlights Lessons Learned From the COVID-19 Crisis in Lung Cancer
The oncology community has risen up as a unified front in the battle against coronavirus disease 2019, launching pivotal research efforts to better understand the enemy and collecting data to develop effective therapeutics to fill the treatment arsenal.
COVID-19 Drives Decreases in Cancer Screening, Diagnoses, and Treatments
October 26th 2020A significant decline in cancer screenings, biopsies, surgeries, office visits, and therapies was observed with variation by cancer type and site of service among senior patients with cancer from March to July 2020, during the coronavirus disease 2019 pandemic.